Literature DB >> 7747486

Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus.

W Sullender1.   

Abstract

Extensive antigenic variation occurs on the attachment glycoprotein G between the two major respiratory syncytial (RS) virus groups. Restriction fragment exchanges were performed among regions of the group A and group B G protein cDNAs to produce chimeric molecules to use in a study of the antigenic structure of the G protein. Proteins were expressed from these chimeric cDNAs using the vaccinia virus T7 bacteriophage polymerase system. Region 1 [A1 or B1, G protein amino acids (aa) 1 to 173] included the cytoplasmic and transmembrane domains and part of the ectodomain, region 2 (A2, aa 174 to 214 in the group A; or B2, aa 174 to 215 in the group B G protein) included the central portion of the ectodomain, and region 3 (A3, aa 215 to 298 in the group A; or B3, aa 216 to 292 in the group B G protein) included the C-terminal region of the ectodomain. The chimeric proteins comprised regions A1B2B3, B1A2A3, A1A2B3, and B1B2A3. Truncated proteins were also produced and consisted of regions A1A2, B1B2, A1, and B1. The expressed proteins were tested by immunofluorescence for reactivity with group-cross-reactive or group-specific G protein monoclonal antibodies (MAbs). Most group-cross-reactive MAbs required the presence of G protein regions 1 or 2 for reactivity. G protein MAbs specific for either group A or group B were dependent on the presence of regions 1, 2, or 3 for reactivity. Thus, each of the three regions of the G protein were found to play a role in reactivity with MAbs, including for each region MAbs with neutralizing activity against RS virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747486     DOI: 10.1006/viro.1995.1231

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.

Authors:  R A Tripp; D Moore; L Jones; W Sullender; J Winter; L J Anderson
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model.

Authors:  Hayat Caidi; Congrong Miao; Natalie J Thornburg; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  Antiviral Res       Date:  2018-04-17       Impact factor: 5.970

3.  Baculovirus expression of the fusion protein gene of bovine respiratory syncytial virus and utility of the recombinant protein in a diagnostic enzyme immunoassay.

Authors:  M K Pastey; S K Samal
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

4.  Detection of antibodies to respiratory syncytial virus attachment and nucleocapsid proteins with recombinant baculovirus-expressed antigens.

Authors:  W Buraphacheep; W J Britt; W M Sullender
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

5.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

6.  Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; Christopher L Parks; Todd S Laughlin; C Kanta Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

Authors:  Congrong Miao; Gertrud U Radu; Hayat Caidi; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

8.  Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; L A Boutilier; N Campeol; K Melville; Todd S Laughlin; C K Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans.

Authors:  Steven Kwilas; Rachael M Liesman; Liqun Zhang; Edward Walsh; Raymond J Pickles; Mark E Peeples
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

10.  Structural Characterization and Binding Studies of the Ectodomain G Protein of Respiratory Syncytial Virus Reveal the Crucial Role of pH with Possible Implications in Host-Pathogen Interactions.

Authors:  Abu Hamza; Zoya Shafat; Zahoor Ahmad Parray; Malik Hisamuddin; Wajihul Hasan Khan; Anwar Ahmed; Fahad N Almajhdi; Mohamed A Farrag; Arif Ahmed Mohammed; Asimul Islam; Shama Parveen
Journal:  ACS Omega       Date:  2021-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.